Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MS Clear all
Completed No phase listed Observational

A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following Relapse

NCT07743281
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 4, 2026, 6:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer

NCT00387465
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Azacitidine 30mg/m2, Entinostat, Azacitidine 40mg/m2
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 4, 2026, 6:53 AM EDT
Completed Not applicable Interventional

Outcomes of Group Dance and Movement Training in Ambulatory MS Patients

NCT05943145
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Group Dance and Movement Training
Other
Lead sponsor
GroundWorks DanceTheater
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 4, 2026, 6:53 AM EDT
Terminated Phase 3 Interventional Results available

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

NCT01633112
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions
fingolimod, glatiramer acetate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
101
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Sep 4, 2026, 6:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Vaccine Biomarker Study in Multiple Sclerosis

NCT05121662
View directory record Official record
Conditions
Multiple Sclerosis, COVID-19
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Sep 4, 2026, 6:53 AM EDT
Recruiting No phase listed Observational

Care in Multiple Sclerosis (MS)

NCT07011914
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 4, 2026, 6:53 AM EDT
Terminated Not applicable Interventional Results available

Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia

NCT02739347
View directory record Official record
Conditions
Schizophrenia, Psychosis
Interventions
Active Trans-cranial direct-current stimulation, Sham Trans-cranial direct current stimulation
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Sep 4, 2026, 6:53 AM EDT
Completed Phase 4 Interventional

AVONEX® Combination Trial - "ACT"

NCT00112034
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Methotrexate, IV methylprednisolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2008 · Synced Sep 4, 2026, 6:53 AM EDT
Recruiting Not applicable Interventional

Miniaturized Breath-based Sensor for the Detection of Hypo- and Hyperglycemia

NCT07696273
View directory record Official record
Conditions
Diabetes, Hyperglycemia, Hypoglycemia (Diabetic)
Interventions
Sensing Device and Tedlar Bags
Device
Lead sponsor
Indiana University
Other
Eligibility
7 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 4, 2026, 6:53 AM EDT
Completed Not applicable Interventional Results available

Improving Prospective Memory Via Telehealth

NCT05129293
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Prospective Memory Intervention, Educational
Behavioral
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 4, 2026, 6:53 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Glucose Consumption in MS Using [F-18]FDG-PET

NCT07087106
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
[F-18]FDG
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 4, 2026, 6:53 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

NCT05147220
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Remibrutinib, Teriflunomide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 4, 2026, 6:53 AM EDT
Not yet recruiting Not applicable Interventional

Physical Activity Intervention for Individuals Newly Diagnosed With MS

NCT07731659
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
COM-B-based Physical Activity Behavior Change Intervention
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 4, 2026, 6:53 AM EDT
Not yet recruiting Phase 1 Interventional

Senolytics for Secondary Progressive MS

NCT07270120
View directory record Official record
Conditions
Multiple Sclerosis (MS) Secondary Progressive
Interventions
Dasatinib and quercetin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 4, 2026, 6:53 AM EDT
Recruiting Not applicable Interventional

Blood Flow Restriction And Veterans With MS

NCT05433103
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Low-Load Exercise with Blood Flow Restriction, Low-Load Exercise Control Group
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 4, 2026, 6:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses

NCT03752307
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Isoxsuprine Hydrochloride, Placebo, Corticosteroid
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 4, 2026, 6:53 AM EDT
Not listed Phase 1 Interventional

Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects

NCT01624714
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Alemtuzumab, Alemtuzumab immunotherapy
Drug
Lead sponsor
Samuel Forrester Hunter, MD, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Sep 4, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Results available

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx

NCT00211887
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Interferon beta 1-a, glatiramer acetate, placebo
Drug · Other
Lead sponsor
Fred Lublin
Other
Eligibility
18 Years to 60 Years
Enrollment
1,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Sep 4, 2026, 6:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls

NCT00391352
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
IFN-β-1a (Rebif®)
Drug
Lead sponsor
Waukesha Memorial Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Waukesha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Sep 4, 2026, 6:53 AM EDT
Active, not recruiting Not applicable Interventional

VIRtual Versus UsuAL In-office Care for Multiple Sclerosis (VIRTUAL-MS)

NCT05660187
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Multiple Sclerosis Clinical Care Delivery via telehealth, Multiple Sclerosis Clinical Care Delivery via standard in clinic visits
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
San Francisco, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 4, 2026, 6:53 AM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis

NCT01416181
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 4, 2026, 6:53 AM EDT
Completed Not applicable Interventional

A Randomized Controlled Trial of a Multicomponent Walking Aid Program for People With MS

NCT04145934
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ADSTEP
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 4, 2026, 6:53 AM EDT
Recruiting Not applicable Interventional

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

NCT06390930
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions
Acute Intermittent Hypoxia, Sham Acute Intermittent Hypoxia
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 4, 2026, 6:53 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Physiology of Interregional Connectivity in the Human Brain

NCT03723434
View directory record Official record
Conditions
Healthy, Stroke, Traumatic Brain Injury, Multiple Sclerosis
Interventions
Single-pulse transcranial magnetic stimulation (spTMS), Paired associative stimulation (PAS), Repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 4, 2026, 6:53 AM EDT